Milsaperidone, a new chemical entity, is the major active metabolite of iloperidone (Fanapt) and had been demonstrated to be bioequivalent to iloperidone.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-oks-milsaperidone-bysanti-bipolar-i-disorder-and-2026a10005m8?src=rss
Author :
Publish date : 2026-02-23 16:43:00
Copyright for syndicated content belongs to the linked Source.